Abstracts tagged "Biologics and biosimilars"

Abstract Number: 634 • 2016 ACR/ARHP Annual Meeting
Use of Biosimilars in Clinical Practice: A Swedish National Register-Based Assessment
Daniela Di Giuseppe¹, Thomas Frisell², Sofia Ernestam^3,4, Helena Forsblad D’Elia⁵, E. Lindqvist⁶, Ulf Lindström⁷, Johan Askling^8,9 and ARTIS, ¹Clinical Epidemiology Unit, Dept. of Medicine, K2, Karolinska institutet, Stockholm, Sweden, ²Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Centre of Rheumatology, Stockholm County Council, Stockholm, Sweden, Stockholm, Sweden, ⁴Clinical Epidemiology unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁵Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, ⁶Department of Rheumatology, Lund University, Lund, Sweden, ⁷Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁸Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden, ⁹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: In March 2015 the first infliximab biosimilars CT-P13 (Remsima™; Inflectra™), entered the Swedish market. The aim of this study was to evaluate the uptake…
Abstract Number: 639 • 2016 ACR/ARHP Annual Meeting
Switching to Biosimilars in Rheumatology: Evidence-Based Practice
Robert J Moots¹, Valderilio F Azevedo², Thomas Dörner³, Eduardo Mysler⁴, Morton Scheinberg⁵, Javier L Coindreau⁶, Ehab Mahgoub⁷ and Lisa Marshall⁷, ¹Department of Musculoskeletal Biology, University of Liverpool, Liverpool, United Kingdom, ²Federal University of Parana and Edumed Health Research Centerand Biotech, Curitiba, Brazil, ³Department of Medicine/Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany, ⁴Organización Médica de Investigación, Buenos Aires, Argentina, ⁵Hospital Israelita Albert Einstein, Sao Paulo, Brazil, ⁶edical Affairs, Pfizer, New York, NY, ⁷Inflammation Global Medical Affairs, Pfizer, Collegeville, PA
Background/Purpose: Biosimilars of originator biologic therapeutics are entering the market, and health care professionals and patients need a clear understanding of these new treatments. The…
Abstract Number: 1507 • 2014 ACR/ARHP Annual Meeting
Patient Perspectives on the Introduction of Subsequent Entry Biologics in Canada
Suneet Sekhon¹, Raman Rai¹, Debbie McClory², Carolyn Whiskin², Melissa Deamude³, Cynthia Mech⁴, Lauri Vanstone², Alpesh Shah⁵, Arthur N. Lau⁶ and William Bensen⁷, ¹Rheumatology, Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ²Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ³Dr William G Bensen Medicine Professional Corp, Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ⁴Dr. William G. Bensen, Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ⁵Epidemiology and Biostatistics, University of Western Ontario, MSc in Clinical Epidemiology, University of Western Ontario, London, ON, Canada, ⁶Rheumatology and Clinical Epidemiology, Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ⁷Division of Rheumatology, McMaster University, Hamilton, ON, Canada
Background/Purpose: Biologic medications have revolutionized the treatment of inflammatory arthritis. Subsequent entry biologics (SEBs) or biosimilars are medications that are similar but not identical to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].